Zynex, Inc. (NASDAQ:ZYXI) CFO Sells $78,800.00 in Stock

Zynex, Inc. (NASDAQ:ZYXI) CFO Daniel J. Moorhead sold 10,000 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $7.88, for a total transaction of $78,800.00. Following the completion of the sale, the chief financial officer now owns 26,299 shares of the company’s stock, valued at approximately $207,236.12. The trade was a 27.55 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Zynex Stock Up 3.6 %

ZYXI stock opened at $8.09 on Monday. The firm has a market cap of $257.63 million, a PE ratio of 53.93 and a beta of 0.49. Zynex, Inc. has a 1 year low of $7.15 and a 1 year high of $13.77. The company has a fifty day simple moving average of $8.30 and a 200 day simple moving average of $8.36. The company has a current ratio of 3.94, a quick ratio of 3.15 and a debt-to-equity ratio of 1.66.

Zynex (NASDAQ:ZYXI) last released its quarterly earnings results on Thursday, October 24th. The company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.01. Zynex had a return on equity of 13.05% and a net margin of 2.49%. The company had revenue of $49.97 million during the quarter, compared to the consensus estimate of $50.83 million. During the same quarter in the prior year, the company posted $0.10 EPS. The firm’s revenue was up .1% on a year-over-year basis. Sell-side analysts anticipate that Zynex, Inc. will post 0.2 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Royal Bank of Canada reduced their price objective on Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. HC Wainwright reissued a “buy” rating and issued a $17.00 price target on shares of Zynex in a research note on Friday, December 6th.

Institutional Trading of Zynex

Institutional investors and hedge funds have recently modified their holdings of the company. Bank of New York Mellon Corp raised its holdings in Zynex by 1.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 192,832 shares of the company’s stock worth $1,797,000 after acquiring an additional 2,954 shares during the period. Principal Financial Group Inc. increased its stake in shares of Zynex by 10.4% in the second quarter. Principal Financial Group Inc. now owns 19,525 shares of the company’s stock worth $182,000 after purchasing an additional 1,846 shares during the period. Quest Partners LLC lifted its position in shares of Zynex by 646.7% during the 2nd quarter. Quest Partners LLC now owns 12,926 shares of the company’s stock worth $120,000 after purchasing an additional 11,195 shares during the last quarter. American Century Companies Inc. boosted its stake in Zynex by 10.1% during the 2nd quarter. American Century Companies Inc. now owns 31,159 shares of the company’s stock valued at $290,000 after purchasing an additional 2,864 shares during the period. Finally, WINTON GROUP Ltd grew its holdings in Zynex by 147.6% in the 2nd quarter. WINTON GROUP Ltd now owns 36,841 shares of the company’s stock valued at $343,000 after buying an additional 21,960 shares during the last quarter. 29.68% of the stock is currently owned by institutional investors and hedge funds.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.